Galectin Therapeutics INC Form 4 insider transactions

Galectin Therapeutics Director Kary Eldred purchased 700 shares of common stock at $3.73 per share, executed under a 10b5-1 plan.

Galectin Therapeutics Inc.'s President and CEO, Joel Lewis, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, executed a series of option exercises and subsequent stock sales totaling 19,442 shares under a pre-arranged 10b5-1 plan.

Galectin Therapeutics Director Harold H. Shlevin exercised stock options and subsequently sold a portion of his common stock holdings on December 17, 2025, under a pre-arranged 10b5-1 plan.

10X Fund, L.P., a 10% owner and director of Galectin Therapeutics Inc., reported an in-kind distribution and a sale of common stock.

A director at Galectin Therapeutics Inc. executed pre-planned option exercises and subsequent share sales in December 2025.

Galectin Therapeutics Director Harold H. Shlevin executed pre-planned sales of common stock after exercising multiple stock options.

An amended SEC Form 4 reveals 10X Fund, L.P., a 10% owner and director, sold 162,069 shares of Galectin Therapeutics Inc. common stock in early December 2025.

10X Fund, a 10% owner of Galectin Therapeutics Inc., sold 150,000 shares of common stock in early December 2025.

Galectin Therapeutics CEO Joel Lewis executed pre-planned transactions, exercising stock options and selling an equivalent number of shares for a profit.

Galectin Therapeutics CFO Jack W. Callicutt executed pre-planned transactions, exercising options and selling 77,920 shares for over $470,000.

Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, executed pre-planned sales of common stock on November 13, 2025, following option exercises.

10X Fund, a 10% owner and director of Galectin Therapeutics Inc., reported the sale of 40,000 shares of common stock for $5.25 per share.

Galectin Therapeutics CEO Joel Lewis exercised stock options and subsequently sold a portion of common stock under a pre-arranged 10b5-1 plan.

Galectin Therapeutics CFO Jack W. Callicutt exercised stock options and subsequently sold an equal number of shares totaling 5,291 under a pre-arranged 10b5-1 plan.

Galectin Therapeutics Inc. CEO Joel Lewis exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 plan.

Galectin Therapeutics CFO Jack W. Callicutt sold common stock on November 5, 2025, through pre-planned option exercises and sales.

Galectin Therapeutics Inc. CEO Joel Lewis executed planned sales of common stock, realizing significant gains from option exercises.

Galectin Therapeutics CFO Jack W. Callicutt executed planned stock option exercises and subsequent sales, realizing significant gains.

10X Fund, L.P., a 10% owner and director of Galectin Therapeutics Inc., reported the sale of 50,000 shares of common stock for approximately $246,800.

Galectin Therapeutics' Chief Financial Officer, Jack W. Callicutt, executed a pre-planned sale of 8,706 common shares following the exercise of stock options.

Galectin Therapeutics President and CEO Joel Lewis exercised options and sold 14,000 shares under a Rule 10b5-1 plan.

Galectin Therapeutics Inc. Director Kary Eldred reported a planned acquisition of 1,000 shares of common stock at $2.925 per share, effective July 21, 2025, under a Rule 10b5-1 plan.

Galectin Therapeutics Inc. Director Kevin D. Freeman has filed a Form 4 indicating a planned future purchase of 5,000 shares of common stock at $2.899 per share on July 17, 2025, under a Rule 10b5-1 trading plan.

Galectin Therapeutics Inc. Director and 10% Owner James C. Czirr significantly increased his direct beneficial ownership of common stock by over 300,000 shares through the exercise of stock options and receipt of dividend shares, despite gifting 20,000 shares to relatives.

Joel Lewis, President and CEO of Galectin Therapeutics, reports the acquisition and disposal of common stock related to deferred stock units (DSUs) and tax withholdings.

Director Harold H. Shlevin acquired 60,000 stock options in Galectin Therapeutics, Inc. on January 23, 2025.

Richard A. Zordani Jr., a director at Galectin Therapeutics, acquired 60,000 stock options on January 23, 2025.

Richard E. Uihlein, a director at Galectin Therapeutics, acquired 32,520 shares and 60,000 stock options as part of his compensation.

Director Elissa J. Schwartz reports the acquisition of stock options in Galectin Therapeutics Inc. on January 23, 2025.